GENEVA – November 23, 2010 –Endosense, a medical technology company focused on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that President and Chief Executive Officer Eric Le Royer will be presenting at the 22nd Annual Piper Jaffray Health Care Conference at 10:30 a.m. on Tuesday, Nov. 30 at the New York Palace Hotel.
Endosense pioneered the field of contact-force sensing in catheter ablation with its
TactiCath? force-sensing ablation catheter. Launched in April 2010, the second generation of the novel device is now used by electrophysiologists across Europe. A growing body of evidence has reinforced the value of force-sensing in improving patient outcomes of catheter ablation procedures.
During the conference presentation, Le Royer will deliver updates on:
• The TactiCath’s significant and growing adoption in Europe, supported by a successful exclusive commercial partnership with BIOTRONIK, a leading cardiovascular medical device company,
• Progress on the EFFICAS study series aimed at proving superiority of force-sensing catheters over standard irrigated catheters, with first patients having already completed chronic follow-up,
• Enrollment in Endosense’s ProForce Registry Study. and
• Endosense’s investigational device exemption (IDE) trial, Toccastar, which has been filed to the U.S Food and Drug Administration.
“Endosense has greatly elevated its profile during 2010, as we have experienced significant adoption of our force-sensing catheter among electrophysiologists across Europe, we have taken the first step towards entering the United States with our PMA filing, and we have gathered evidence from our TOCCATA trial that twelve month success of ablation procedures is statistically correlated with contact force applied during procedures,” said Le Royer. “We believe that data from our ongoing studies will only continue to validate the distinctive value of contact-force sensing for improving patient outcomes in catheter ablation procedures, and we look forward to making this potential the standard of care for physicians and their patients across the world.”
The TactiCath force-sensing ablation catheter and its accompanying TactiSys system are indicated for the treatment of atrial fibrillation (AF) and supraventricular tachycardia (SVT). BIOTRONIK is the exclusive distributor of the TactiCath in Europe, Latin America, Canada, Africa, and Middle East. The TactiCath is not yet available in the United States.
About the TactiCath
Endosense’s TactiCath is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical validation, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact-force sensing during catheter ablation. The TactiCath has the potential to improve the effectiveness, safety and reproducibility of catheter ablation treatment of cardiac rhythm disorders, including AF.
Founded in Geneva in 2003, Endosense is a medical technology company focused on improving efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias. The company has pioneered the use of contact force measurement in catheter ablation, with the development of its proprietary Touch+® sensor technology. Endosense’s flagship product is the TactiCath, the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure.
Endosense is backed by Edmond de Rothschild Investment Partners, Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie. For more information, visit www.endosense.com.